FIELD: medicine.
SUBSTANCE: invention relates to a method for reducing or alleviating seizures in a patient diagnosed with refractory epilepsy, or Dravet's syndrome, said method comprising administering fenfluramine and cannabidiol, thereby modulating synthesis of norfenfluramine, wherein synthesis of norfenfluramine is reduced leading to higher levels of fenfluramine.
EFFECT: reduced dosage of the first medicinal product with maintained efficiency equivalent to that of higher doses of the first medicinal product when administered as monotherapy.
10 cl, 7 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE | 2016 |
|
RU2740919C2 |
| METHODS FOR TREATMENT OF DOOSE SYNDROME, USING FENFLURAMINE | 2018 |
|
RU2784524C2 |
| CONTROL SYSTEM FOR MANAGING DISTRIBUTION OF MEDICINAL PRODUCTS | 2015 |
|
RU2704749C2 |
| THE COMPOSITION OF FENFLURAMINE, COMPATIBLE WITH A KETOGENIC DIET | 2018 |
|
RU2778848C2 |
| METHODS OF TREATING DRAVET SYNDROME | 2018 |
|
RU2767661C2 |
| METHODS OF TREATING OR PREVENTING THROMBOSIS OR EMBOLISM | 2011 |
|
RU2611662C2 |
| IDENTIFICATION OF PATIENTS' REACTION TO ADMINISTRATION OF S1P RECEPTOR MODULATOR | 2013 |
|
RU2785736C2 |
| FENFLURAMINE COMPOSITIONS AND METHODS FOR PRODUCTION THEREOF | 2016 |
|
RU2731179C2 |
| INJECTION OF DEUTERATED CFTR AMPLIFIERS | 2016 |
|
RU2761344C2 |
| ORGANIC COMPOUNDS | 2017 |
|
RU2733975C2 |
